Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | XIAP | P98170 | 1/20 | 0.31 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.31 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.31 |
| ▸ | FSHR | P23945 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | CASP1 | P29466 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2912534 | 0.83 | KMT2A (0.39) | MAPK1KMT2AATAD2ALDH1A1MAPT | |
| SCHEMBL2723741 | 0.82 | SLC22A12 (0.38) | SLC22A12NOTUMXIAPBIRC2 | |
| SCHEMBL2720836 | 0.78 | ESPL1 (0.39) | SLC22A12KDM4EALDH1A1LMNAMAPT | |
| SCHEMBL447188 | 0.78 | NOTUM (0.50) | SLC22A12NOTUMKMT2ABIRC2LMNA | |
| SCHEMBL11988460 | 0.74 | DRD2 (0.36) | KMT2AALDH1A1MAPT | |
| SCHEMBL31481087 | 0.74 | NOTUM (0.62) | NOTUMXIAPBIRC2ATAD2FSHR | |
| SCHEMBL31481108 | 0.74 | NOTUM (0.62) | NOTUMXIAPBIRC2ATAD2FSHR | |
| SCHEMBL395606 | 0.74 | NOTUM (0.62) | NOTUMXIAPBIRC2ATAD2FSHR | |
| SCHEMBL22346077 | 0.74 | KMT2A (0.42) | SLC22A12KMT2AKDM4EALDH1A1LMNA | |
| SCHEMBL4000282 | 0.74 | ALDH1A1 (0.35) | NOTUMKMT2AFSHRKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011072241-A9 | 4-OXO-1H-QUINOLINE-3-CARBOXAMIDES AS MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-14 | — | — | WO | disclosed |
| EP-2445902-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USES AS INHIBITORS OF PI3K ACTIVITY | Amgen, Inc (US) | 2012-05-02 | — | — | EP | disclosed |
| EP-2376448-A2 | IMPROVED METHOD FOR THE PREPARATION OF 1-ACETYL-6-AMINO-3,3-DIMETHYL-2,3-DIHYDROINDOLE | Amgen, Inc (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010151737-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-29 | — | — | WO | disclosed |
| WO-2010071828-A2 | IMPROVED METHOD FOR THE PREPARATION OF 1-ACETYL-6-AMINO-3,3-DIMETHYL-2,3-DIHYDROINDOLE | AMGEN INC. (US) | 2010-06-24 | — | — | WO | disclosed |
| EP-1885369-A2 | FUSED HETEROCYCLIC COMPOUNDS, AND COMPOSITIONS AND USES THEREOF | Renovis, Inc. (US) | 2008-02-13 | — | — | EP | disclosed |
| US-20070259891-A1 | Heterocycle-Substituted Cyclic Urea Derivatives, Preparation Thereof And Pharmaceutical Use Thereof As Kinase Inhibitors | AVENTIS PHARMA S.A. (FR) | 2007-11-08 | — | — | US | disclosed |
| EP-1773828-A1 | HETEROCYCLE -SUBSTITUTED CYCLIC UREA DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS | Aventis Pharma S.A. (FR) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006119504-A2 | FUSED HETEROCYCLIC COMPOUNDS, AND COMPOSITIONS AND USES THEREOF | RENOVIS, INC. (US) | 2006-11-09 | — | — | WO | disclosed |
| WO-2006118598-A1 | BICYCLOHETEROARYLAMINE COMPOUNDS AS ION CHANNEL LIGANDS AND USES THEREOF | RENOVIS, INC. (US) | 2006-11-09 | — | — | WO | disclosed |
| EP-1713484-A2 | COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2006-10-25 | — | — | EP | disclosed |
| WO-2006010642-A1 | HETEROCYCLE-SUBSTITUTED CYCLIC UREA DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2006-02-02 | — | — | WO | disclosed |
| WO-2005070891-A2 | COMPOUNDS AND METHODS OF USE | AMGEN INC (US) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259891-A1 | Heterocycle-Substituted Cyclic Urea Derivatives, Preparation Thereof And Pharmaceutical Use Thereof As Kinase Inhibitors | CDK1, PRKAR2B, MAP3K19 | SLC22A12 3706/4885NOTUM 4070/4885MAPK1 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.